Mucosal tumor vaccination delivering endogenous tumor antigens protects against pulmonary breast cancer metastases

• DOI: 10.1136/jitc-2023-008652
• Publication Date: 2024-03-08T07:00:16Z
• Authors: Friederike Oltmanns; Ana Vieira Antão; Pascal Irrgang; Vera Viherlehto; Leticia Jörg; Anna Schmidt; Jannik T Wagner; Michael Rückert; Ann-Sophie Flohr; Carol Imanuel Gep...; Benjamin Frey; Wibke Bayer; Claudia Gravekamp; Matthias Tenbusch; Udo Gaipl; Dennis Lapuente
• Keywords: 0303 health sciences; 03 medical and health sciences; Medizin; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Basic Tumor Immunology; RC254-282

Background Generally, early-stage breast cancer has a good prognosis. However, if it spreads systemically, especially with pulmonary involvement, prospects worsen dramatically. Importantly, tumor-infiltrating T cells contribute to tumor control, particularly intratumoral tissue-resident memory phenotype are associated an improved clinical outcome. Methods Here, we use adenoviral vector vaccine encoding endogenous tumor-associated antigens adjuvanted interleukin-1β induce tumor-specific (TRM) in the lung for prevention and treatment of metastases murine 4T1 model. Results The mucosal delivery was highly efficient establishing TRM lung. Concomitantly, single vaccination reduced growth survival prophylactic treatment. Vaccine-induced contributed these protective effects. In therapeutic setting, induced pronounced cell infiltration into but resulted only minor restriction disease progression. combination stereotactic radiotherapy, increased time rate tumor-bearing mice. Conclusion summary, our study demonstrates that is promising strategy harness power antitumor its potential state-of-the-art treatments.